Identification of potential chemoresistance genes in osteosarcoma

Anticancer Research

Volumn 28, Issue 2 A, 2008, Pages 673-679

  Walters, Denise Katherine ^a   Steinmann, Patrick ^a   Langsam, Bettina ^a   Schmutz, Silvia ^a   Born, Walter ^a   Fuchs, Bruno ^a  

^a BALGRIST UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Chemoresistance; Gene profiling; MG 63; Osteosarcoma

Indexed keywords

CISPLATIN; DOXORUBICIN; ETOPOSIDE;

ABCG2 GENE; ADD3 GENE; ANALYTIC METHOD; ARTICLE; CANCER RESISTANCE; CELL LINE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; GENE; GENE EXPRESSION; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NMT2 GENE; NUCLEOTIDE SEQUENCE; OSTEOSARCOMA; PRIORITY JOURNAL; PTN GENE; WNT5ALPHA GENE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OSTEOSARCOMA;

EID: 42549084233     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Marina N, Gebhardt M, Teot L and Gorlick R: Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 9: 422-441, 2004.
2. Meyers PA, Heller G, Healey JH, Huvos A, Applewhite A, Sun M and LaQuaglia M: Osteogenic sarcoma with clinically detectable metastasis at initial presentation. J Clin Oncology 11: 449-453, 1993.
3. Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A and Shuster J: Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop 270: 8-14, 1991.
4. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S and Goodnight J: Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5: 21-26, 1987.
5. Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C and Huvos AG: Primary osteogenic sarcoma: the rationale for preoperative chemotherapy and delayed surgery. Cancer 43: 2163-2177, 1979.
6. Provisor AJ, Ettinger LJ, Nachman JB, Provisor AJ, Ettinger LJ, Nachman JB, Krailo MD, Makley JT, Yunis EJ, Huvos AG, Betcher DL, Baum ES, Kisker CT and Miser JS: Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children's Cancer Group. J Clin Oncol 5: 76-84, 1997.
7. Mintz MB, Sowers R, Brown KM, Hilmer SC, Mazza B, Huvos AG, Meyers PA, Lafleur B, McDonough WS, Henry MM, Ramsey KE, Antonescu CR, Chen W, Healey JH, Daluski A, Berens ME, Macdonald TJ, Gorlick R and Stephan DA: An expression signature classifies chemotherapy-resistant pediatric osteosarcoma. Cancer Res 65: 1748-1754, 2005.
8. Man TK, Chintagumpala M, Visvanathan J, Shen J, Perlaky L, Hicks J, Johnson M, Davino N, Murray J, Helman L, Meyer W, Triche T, Wong KK and Lau CC: Expression profiles of osteosarcoma that can predict response to chemotherapy. Cancer Res 65: 8142-8150, 2005.
9. Ochi K, Daigo Y, Katagiri T, Nagayama S, Tsunoda T, Myoui A, Naka N, Araki N, Kudawara I, Ieguchi M, Toyama Y, Toguchida J, Yoshikawa H and Nakamura Y: Prediction of response to neoadjuvant chemotherapy for osteosarcoma by gene-expression profiles. Int J Can 24: 647-655, 2004.
10. Walters DK, Muff R, Langsam B, Gruber P, Born W and Fuchs B: Taurolidine: A novel anti-neoplastic agent induces apoptosis of osteosarcoma cell lines. Investigational New Drugs 25: 305-312, 2007.
11. Tusher VG, Tibshirani R and Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci 98: 5116-5121, 2001.
12. Kadomatsu K and Muramatsu T: Midkine and pleiotrophin in neural development and cancer. Cancer Lett 204: 127-143, 2004.
13. Peria FM, Neder L, Marie SK, Rosemberg S, Oba-Shinjo SM, Colli BO, Gabbai AA, Malheiros SM, Zago MA, Panepucci RA, Moreira-Filho CA, Okamoto OK and Carlotti CG Jr: Pleiotrophin expression in astrocytic and oligodendroglial tumors and its correlation with histological diagnosis, microvascular density, cellular proliferation and overall survival. J Neurooncol 84: 255-261, 2007.
14. Chen H, Gordon MS, Campbell RA, Li M, Wang CS, Lee HJ, Sanchez E, Manyak SJ, Gui D, Shalitin D, Said J, Chang Y, Deuel TF, Baritaki S, Bonavida B and Berenson JR: Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood 110: 287-295, 2007.
15. Souttou B, Juhl H, Hackenbruck J, Röckseisen M, Klomp HJ, Raulais D, Vigny M and Wellstein A: Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. J Natl Cancer Inst 90: 1468-1473, 1998.
16. Zhang N, Zhong R and Deuel TF: Domain structure of pleiotrophin required for transformation. J Biol Chem 274: 12959-12962, 1999.
17. Citterio L, Tizzoni L, Catalano M, Zerbini G and Bianchi G: Expression analysis of the human adducin gene family and evidence of ADD2 beta4 multiple splicing variants. Biochem Biophys Res Commun 309: 359-367, 2003.
18. Györffy B, Surowiak P, Kiesslich O, Denkert C, Schäfer R, Dietel M and Lage H: Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer 118: 1699-1712, 2006.
19. Nisole S, Stoye JP and Saib A: TRIM family proteins: retroviral restriction and antiviral defence. Nature Reviews Microbiology 3: 799-808, 2005.
20. Obad S, Olofsson T, Mechti N, Gullberg U and Drott K: Expression of the IFN-inducible p53-target gene TRIM22 is down-regulated during erythroid differentiation of human bone marrow. Leuk Res 31: 995-1001, 2007.
21. Moon RT, Brown JD and Torres M: WNTs modulate cell fate and behaviour during vertebrate development. Trends in Genetics 13: 157-162, 1997.
22. Kohn AD and Moon RT: Wnt and calcium signaling: beta-catenin-independent pathways. Cell Calcium 38: 439-446, 2005.
23. Giles RH, van Es JH and Clevers H: Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta 1653: 1-24, 2003.
24. Pukrop T, Klemm F, Hagemann T, Gradl D, Schulz M, Siemes S, Trümper L and Binder C: Wnt5a signaling is critical for macrophage-induced invasion of breast cancer cell lines. Proc Natl Acad Sci 103: 5454-5459, 2006.
25. Kurayoshi M, Oue N, Yamamoto H, Kishida M, Inoue A, Asahara T, Yasui W and Kikuchi A: Expression of Wnt5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. Cancer Res 66: 10439-10448, 2006.
26. Kremenevskaja N, von Wasielewski R, Rao AS, Schofl C, Andersson T and Brabant G: Wnt5a has tumor suppressor activity in thyroid carcinoma. Oncogene 24: 2144-2154, 2005.
27. Liang H, Chen Q, Coles AH, Anderson SJ, Pihan G, Bradley A, Gerstein R, Jurecic R and Jones SN: Wnt5a inhibits B cell proliferation and functions as a tumor suppressor in hematopoietic tissue. Cancer Cell 4: 349-360, 2003.
28. Blanc E, Roux GL, Bénard J and Raguénez G: Low expression of Wnt-5a gene is associated with high-risk neuroblastoma. Oncogene 24: 1277-1283, 2005.
29. Jonsson M, Dejmek J, Bendahl PO and Andersson T: Loss of Wnt-5a protein is associated with early relapse in invasive ductal breast carcinomas. Cancer Res 62: 409-416, 2002.
30. Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci 95: 15665-15670, 1998.
31. Maliepaard M, van Gastelen MA, de Jong LA, Pluim D, van Waardenburg RC, Ruevekamp-Helmers MC, Floot BG and Schellens JH: Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line. Cancer Res 59: 4559-4563, 1999.
32. Ross DD, Yang W, Abruzzo LV, Dalton WS, Schneider E, Lage H, Dietel M, Greenberger L, Cole SP and Doyle LA: Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J Natl Cancer Inst 91: 429-433, 1999.
33. Gillet JP, Efferth T and Remade J: Chemotherapy-induced resistance by ATP-binding cassette transporter genes. Biochim Biophys Acta 1775: 237-262, 2007.